Pablo J. Cagnoni's most recent trade in Incyte Corp. was a trade of 18,668 Common Stock done at an average price of $100.9 . Disclosure was reported to the exchange on Feb. 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Incyte | Pablo J. Cagnoni | President, R&D | Sale of securities on an exchange or to another person at price $ 100.91 per share. | 19 Feb 2026 | 18,668 | 234,800 (0%) | 0% | 100.9 | 1,883,788 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2026 | 13,093 | 7,182 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.76 per share. | 19 Feb 2026 | 13,093 | 247,893 (0%) | 0% | 61.8 | 808,624 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2026 | 5,575 | 16,268 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.18 per share. | 19 Feb 2026 | 5,575 | 253,468 (0%) | 0% | 61.2 | 341,079 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2026 | 28,475 | 28,475 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2025 | 43,846 | 43,846 | - | - | Performance Shares | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2025 | 39,471 | 39,471 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2025 | 17,538 | 234,800 (0%) | 0% | 0 | Common Stock | |
| Incyte | Pablo J. Cagnoni | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.25 per share. | 14 Jul 2025 | 2,628 | 217,262 (0%) | 0% | 68.3 | 179,361 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.98 per share. | 14 Jul 2025 | 1,280 | 219,890 (0%) | 0% | 70.0 | 89,574 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 40,289 | 40,289 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 44,411 | 44,411 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 19,851 | 221,919 (0%) | 0% | 0 | Common Stock | |
| Incyte | Pablo J. Cagnoni | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 64.25 per share. | 15 Jul 2024 | 749 | 221,170 (0%) | 0% | 64.2 | 48,123 | Common Stock |
| Incyte | Pablo Cagnoni J. | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 21,843 | 21,843 | - | - | Employee Stock Option (right to buy) | |
| Fusion Pharmaceuticals Inc | Pablo J. Cagnoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Pablo J. Cagnoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) |